386 related articles for article (PubMed ID: 9773737)
1. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.
Chiasson JL; Gomis R; Hanefeld M; Josse RG; Karasik A; Laakso M
Diabetes Care; 1998 Oct; 21(10):1720-5. PubMed ID: 9773737
[TBL] [Abstract][Full Text] [Related]
2. Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data.
Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
Diabetologia; 2004 Jun; 47(6):969-75; discussion 976-7. PubMed ID: 15164169
[TBL] [Abstract][Full Text] [Related]
3. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial.
Chiasson JL
Endocr Pract; 2006; 12 Suppl 1():25-30. PubMed ID: 16627376
[TBL] [Abstract][Full Text] [Related]
4. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance.
Chiasson JL; Josse RG; Leiter LA; Mihic M; Nathan DM; Palmason C; Cohen RM; Wolever TM
Diabetes Care; 1996 Nov; 19(11):1190-3. PubMed ID: 8908378
[TBL] [Abstract][Full Text] [Related]
5. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance.
Chiasson JL
Diabet Med; 1996; 13(3 Suppl 2):S23-4. PubMed ID: 8689858
[TBL] [Abstract][Full Text] [Related]
6. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
JAMA; 2003 Jul; 290(4):486-94. PubMed ID: 12876091
[TBL] [Abstract][Full Text] [Related]
7. [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].
Flórez H
Invest Clin; 1997 Mar; 38(1):39-52. PubMed ID: 9235072
[TBL] [Abstract][Full Text] [Related]
8. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance.
Hanefeld M; Chiasson JL; Koehler C; Henkel E; Schaper F; Temelkova-Kurktschiev T
Stroke; 2004 May; 35(5):1073-8. PubMed ID: 15073402
[TBL] [Abstract][Full Text] [Related]
9. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C;
Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545
[TBL] [Abstract][Full Text] [Related]
10. [Drug therapy in subjects with impaired glucose tolerance].
Kawamori R; Yoshii H
Nihon Rinsho; 1996 Oct; 54(10):2750-3. PubMed ID: 8914439
[TBL] [Abstract][Full Text] [Related]
11. Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial.
Hanefeld M; Karasik A; Koehler C; Westermeier T; Chiasson JL
Diab Vasc Dis Res; 2009 Jan; 6(1):32-7. PubMed ID: 19156626
[TBL] [Abstract][Full Text] [Related]
12. Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM.
Berkowitz K; Peters R; Kjos SL; Goico J; Marroquin A; Dunn ME; Xiang A; Azen S; Buchanan TA
Diabetes; 1996 Nov; 45(11):1572-9. PubMed ID: 8866563
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitus-The STOP-NIDDM risk-score.
Tuomilehto J; Lindström J; Hellmich M; Lehmacher W; Westermeier T; Evers T; Brückner A; Peltonen M; Qiao Q; Chiasson JL
Diabetes Res Clin Pract; 2010 Feb; 87(2):267-74. PubMed ID: 20022651
[TBL] [Abstract][Full Text] [Related]
14. Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial.
Holman RR; Bethel MA; Chan JC; Chiasson JL; Doran Z; Ge J; Gerstein H; Huo Y; McMurray JJ; Ryden L; Liyanage W; Schröder S; Tendera M; Theodorakis MJ; Tuomilehto J; Yang W; Hu D; Pan C;
Am Heart J; 2014 Jul; 168(1):23-9.e2. PubMed ID: 24952856
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
Zeymer U
Int J Cardiol; 2006 Feb; 107(1):11-20. PubMed ID: 16337493
[TBL] [Abstract][Full Text] [Related]
16. Transient impaired glucose tolerance in South African Indians does not carry a risk for progression to NIDDM.
Motala AA; Omar MA; Gouws E
Diabetes Care; 1997 Jul; 20(7):1101-7. PubMed ID: 9203444
[TBL] [Abstract][Full Text] [Related]
17. The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance.
Laube H; Linn T; Heyen P
Exp Clin Endocrinol Diabetes; 1998; 106(3):231-3. PubMed ID: 9710365
[TBL] [Abstract][Full Text] [Related]
18. [Prevalence of type II diabetes mellitus in population of Krakow].
Szurkowska M; Szybiński Z; Nazim A; Szafraniec K; Jedrychowski W
Pol Arch Med Wewn; 2001 Sep; 106(3):771-9. PubMed ID: 11928585
[TBL] [Abstract][Full Text] [Related]
19. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.
Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
Lancet; 2002 Jun; 359(9323):2072-7. PubMed ID: 12086760
[TBL] [Abstract][Full Text] [Related]
20. A review of the economic evidence for acarbose in the prevention of diabetes and cardiovascular events in individuals with impaired glucose tolerance.
Josse RG; McGuire AJ; Saal GB
Int J Clin Pract; 2006 Jul; 60(7):847-55. PubMed ID: 16858756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
